Biotech

Bristol Myers Squibb to Participate in Raymond James Virtual 42nd Annual Institutional Investors Conference

Bristol Myers Squibb (NYSE: BMY) today announced that the company will take part in a fireside chat at Raymond James' Virtual 42 nd Annual Institutional Investors Conference, which will be webcast on Tuesday, March 2, 2021. David Elkins , Executive Vice President, Chief Financial Officer will answer questions about the company at 8:20 a.m. ET.

Investors and the general public are invited to listen to a live webcast of the session at http://investor.bms.com . Material related to the company's presentation will be available at the same website at the start of the live webcast. An archived edition of the session will be available later that day.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook , and Instagram .

Bristol Myers Squibb

Media:
media@bms.com

Investor Relations:
Tim Power
609-252-7509
timothy.power@bms.com

Nina Goworek
908-673-9711
nina.goworek@bms.com

News Provided by Business Wire via QuoteMedia

The Conversation (0)
Boosh Hires Pixie Brands and Multi Brands Sampling Co for BC Promos and Store Sampling

Boosh Hires Pixie Brands and Multi Brands Sampling Co for BC Promos and Store Sampling

Boosh Plant-Based Brands Inc. (CSE: VEGI) (OTCQB: VGGIF) (FSE: 77I) ("Boosh" or the "Company"), a premier plant-based brand in the "better for you" food sector, announced today it is working with Pixie Brands @meetpixiebrands and Multi Brand Sampling Co @multibrandsmaplingco to promote and enhance sales at store level for all Boosh and Beanfields brands in BC.

Founded by CPG founder April Angelini, Pixie Brands offers a relationship-based, boots on the ground approach to help small and medium brands SHINE. They offer sales and distributor support and organize In-Store Events.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

AMGEN RESPONDS TO FTC ACTION RE: PROPOSED ACQUISITION OF HORIZON THERAPEUTICS

Amgen (NASDAQ:AMGN) today issued the following statement in response to the U.S. Federal Trade Commission's (FTC) complaint seeking to block the company's proposed acquisition of Horizon Therapeutics plc:

"Amgen is disappointed by the FTC's decision and remains committed to completing this acquisition, which will bring significant benefits to patients suffering from very serious rare diseases in the U.S. and around the world.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
BriaCell Announces $4 Million Strategic Investment and Clinical Alliance with Prevail Partners, LLC and Prevail InfoWorks, Inc.

BriaCell Announces $4 Million Strategic Investment and Clinical Alliance with Prevail Partners, LLC and Prevail InfoWorks, Inc.

  • Prevail Partners, LLC to purchase 463,408 BriaCell common shares at a price of $8.63 for gross proceeds of $4 million, representing a 20% premium to the trailing thirty (30) trading day VWAP.
  • Prevail InfoWorks, Inc. to act as Contract Research Organization (CRO) for BriaCell's upcoming pivotal study, expected to commence in 2023.

briacell therapeutics corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, announces that the Company has signed a Master Service and Technology Agreement ("MSTA") agreement with Prevail InfoWorks, Inc. ("InfoWorks"), a Philadelphia, PA based Contract Research Organization (CRO), to provide clinical services and technologies for BriaCell's upcoming pivotal study in advanced metastatic breast cancer. Services include clinical site coordination, project management, clinical monitoring and pharmacovigilance (safety management) services, and the use of InfoWork's integrated real-time data analytics platform, The Single Interface ® for clinical support and real-time data analysis.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
  Sirona Biochem Chief Scientific Officer Géraldine Deliencourt-Godefroy

Sirona Biochem Eyes Licensing Deal for Anti-aging Compound After Clinical Trial Results

Sirona Biochem (TSXV:SBM) is looking forward to securing a licensing deal after a clinical trial for its novel anti-aging compound TFC-1326 showed exceptional results, according to Géraldine Deliencourt-Godefroy, the company’s chief scientific officer.

“We have ongoing discussions with different partners that have shown interest in this compound … we have an event in Boston where we (will) share with other prospects (the) best results in order to find a way to license this compound,” Deliencourt-Godefroy said.

The clinical trial was conducted among 20 volunteers who used the compound in cream form two times a day for three months.

Keep reading...Show less
Sirona Biochem: Investing News Network Interview with CSO, Dr. Geraldine Deliencourt-Godefroy

Sirona Biochem: Investing News Network Interview with CSO, Dr. Geraldine Deliencourt-Godefroy

Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") is pleased to announce that the Investing News Network has published an exclusive video interview with Dr. Geraldine Deliencourt-Godefroy, the Chief Scientific Officer of Sirona.

In the interview, Dr. Deliencourt-Godefroy shares the remarkable story behind her groundbreaking discovery in anti-aging, TFC-1326, and discusses the recent clinical trial that showed exceptional results in aging skin without any adverse side effects.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
dna strand 3d rendering

Biotech Stocks: 5 Biggest Companies in 2023

What are the top biotech companies? The following five stocks have market capitalizations worth billions of dollars and operate in countries all around the globe.

Plus, these big-name biotech players have pipelines stuffed with potentially disruptive products — and enough revenue to recover should some of those products fail.

This means that investors can experience the excitement of biotech investing while minimizing risk. Although returns are never guaranteed, company size can insulate investors from volatility.

Keep reading...Show less

Latest Press Releases

Related News

×